Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and Prostatic Neoplasms

plerixafor has been researched along with Prostatic Neoplasms in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, ZF; Zhou, X; Zhu, WB1
Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC1
Fujita, K; Hatano, K; Kaneda, Y; Murakami, K; Nagahara, A; Nakai, Y; Nakayama, M; Nimura, K; Nonomura, N; Tsuchiya, M; Uemura, M; Yamaguchi, S1
Biordi, L; Di Cesare, E; Festuccia, C; Gravina, GL; Jannini, EA; Mancini, A; Mattei, C; Muzi, P; Pompili, S; Ricevuto, E; Ventura, L1
Cher, ML; Chinni, SR; Conley-LaComb, MK; Heath, EI; Kim, S; Li, Y; Semaan, L; Singareddy, R1
Asara, JM; Avigan, DE; Balk, SP; Cantley, LC; Clohessy, JG; Csizmadia, E; Elemento, O; Gehring, MP; Helenius, K; Karp, JM; Kelly, K; Landon-Brace, N; Levantini, E; Montaser, L; Morgan, TM; Novak, J; Olson, BM; Pandolfi, PP; Patnaik, A; Pyzer, AR; Rosenblatt, JM; Signoretti, S; Solanki, A; Swanson, KD; Thornley, TB; Timmons, JJ; Wang, LC; Wang, Y; Ye, H1
Banie, L; Li, LC; Lin, CS; Lin, G; Lue, TF; Ning, H; Wang, G; Yang, R1
Bouchez, LC; Cho, CY; Dubrovska, A; Elliott, J; Kularatne, SA; Reddy, VA; Salamone, RJ; Schepotin, IB; Schultz, PG; Stakhovsky, AE; Telegeev, GD; Trussell, C; Wang, Y; Watson, J; Yan, F1
Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM1
La Montagna, G; Mognetti, B; Pagliaro, P; Penna, C; Perrelli, MG1

Other Studies

10 other study(ies) available for plerixafor and Prostatic Neoplasms

ArticleYear
AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Journal of cellular physiology, 2019, Volume: 234, Issue:7

    Topics: Animals; Benzylamines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Chemokine CXCL12; Cyclams; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Liver Neoplasms; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Phosphorylation; Prostatic Neoplasms; Receptors, CXCR4; RNA, Messenger; Signal Transduction

2019
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
    International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment

2013
Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cyclams; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Male; MAP Kinase Signaling System; Mice, Nude; Mice, SCID; Neoplasm, Residual; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Signal Transduction; Taxoids

2013
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    The Prostate, 2015, Volume: 75, Issue:12

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Benzylamines; Blotting, Western; Bone Neoplasms; Cell Adhesion; Cell Movement; Chemokine CXCL12; Coculture Techniques; Cyclams; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds; Heterografts; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Nude; Peptides; Prostatic Neoplasms; Receptors, CXCR4; Tomography, X-Ray Computed; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2015
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
    Molecular cancer, 2016, 11-03, Volume: 15, Issue:1

    Topics: Animals; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Models, Animal; ErbB Receptors; GTP-Binding Protein alpha Subunits, Gi-Go; Heterocyclic Compounds; Humans; Male; Membrane Microdomains; Mice; Phosphorylation; Prostatic Neoplasms; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays

2016
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.
    Cancer discovery, 2017, Volume: 7, Issue:7

    Topics: Anilides; Animals; Benzylamines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; HMGB1 Protein; Humans; Immunity, Innate; Male; Mice; Neutrophils; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Tumor Microenvironment; Tumor Suppressor Protein p53

2017
Effects of transplantation of adipose tissue-derived stem cells on prostate tumor.
    The Prostate, 2010, Jul-01, Volume: 70, Issue:10

    Topics: Adipose Tissue; Animals; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Fibroblast Growth Factor 2; Heterocyclic Compounds; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neovascularization, Pathologic; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Stem Cell Transplantation; Vascular Endothelial Growth Factor A

2010
CXCR4 expression in prostate cancer progenitor cells.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Adhesion; Cell Proliferation; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, CXCR4; Taxoids

2012
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012
Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1α.
    Journal of cellular and molecular medicine, 2013, Volume: 17, Issue:2

    Topics: Animals; Anti-HIV Agents; Benzylamines; Blotting, Western; Bone Marrow; Cell Movement; Cell Proliferation; Chemokine CXCL12; Culture Media, Conditioned; Cyclams; Heterocyclic Compounds; Humans; Male; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Rats; Tumor Cells, Cultured

2013